Related Experiment Video
Updated: Mar 6, 2026
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Identification of novel B-RafV600E inhibitors employing FBDD strategy
Peng-Fei Wang1, Han-Yue Qiu1, Ze-Feng Wang1
1State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, People's Republic of China.
Abstract:
B-Raf kinase is the key point in a main branch of mitogen-activated protein kinase pathways and some of its mutations, such as the V600E mutation, lead to the persistent activation of ERK signaling and the trigger of severe diseases, including melanoma and other somatic cancers. Several potent drugs have been approved to treat B-Raf-related tumors, however, cases of resistance and relapse have been reported universally. Hence, differential scaffolds are in need to alleviate the scarcity of drugs and benefit the therapy of B-Raf-mutant cancers. Herein we report our recent work on the construction of novel B-RafV600E inhibitors employing fragment-based drug design strategy. In this research, we decomposed known inhibitors to fragments and rebuilt new candidates using these blocks according to the evaluation of their potential. Lead compounds were synthesized after selection by means of virtual screening and molecular dynamics validation. Afterwards, we tested the pharmacological efficiency of these entities both in vitro and in vivo utilizing A375 xenograft model. The results favored our rational design intention and hinted this new kind of inhibitors might be helpful in the further explorations of potent agents.
Insights
Novel B-Raf inhibitors were designed using fragment-based drug discovery to combat resistance in B-Raf V600E-mutant cancers. These new compounds show promise for treating melanoma and other B-Raf-driven tumors.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- B-Raf kinase is crucial in MAPK pathways; mutations like V600E cause persistent ERK activation, driving cancers such as melanoma.
- Approved B-Raf inhibitors face widespread resistance and relapse, necessitating novel therapeutic scaffolds.
Purpose of the Study:
- To develop novel B-Raf V600E inhibitors using a fragment-based drug design (FBDD) strategy.
- To address the unmet need for effective treatments against B-Raf-mutant cancers.
Main Methods:
- Decomposition of known inhibitors into fragments and reconstruction of new candidates.
- Virtual screening and molecular dynamics for lead compound selection and validation.
- In vitro and in vivo pharmacological evaluation using A375 xenograft models.
Main Results:
- Successful rational design and synthesis of novel B-Raf V600E inhibitors.
- Demonstrated pharmacological efficacy of the developed compounds in preclinical models.
- Validation of the FBDD approach for generating potent kinase inhibitors.
Conclusions:
- The novel B-Raf inhibitors developed show potential for treating B-Raf-mutant cancers.
- This FBDD strategy offers a promising avenue for overcoming drug resistance in oncology.
- Further exploration of these inhibitors could lead to improved cancer therapies.
